ANBL1531, A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or AlK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

This randomized clinical trial is examining whether the addition of radio- labelled MIBG or Crizotinib will improve the survival of high risk Neuroblastoma patients, as compared to standard treatment. Patients will be non-randomly assigned to Crizotinib based on tumor testing. All other patients will be randomized to receive standard therapy or standard therapy + MIBG.

Are you Eligible? (Inclusion Criteria)

• Between 1 and 30 years of age
• Have a diagnosis of High Risk Neuroblastoma
• Enrolled on ANBL00B1
• Patients must also meet all other eligibility criteria as outlined in the study